Pregenzer-Wenzler Arianna, Abraham Jo, Barrell Kelsey, Kovacsovics Tibor, Nativi-Nicolau Jose
Cardiac Amyloidosis Program, University of Utah School of Medicine, Salt Lake City, Utah.
Huntsman Cancer Institute, Salt Lake City, Utah.
JACC Heart Fail. 2020 Sep;8(9):701-711. doi: 10.1016/j.jchf.2020.03.007. Epub 2020 Jul 8.
Cardiac amyloidosis is a growing field, with advancements in diagnosis and management. Cardiac biomarkers are used to predict survival and to develop severity staging systems. Cardiac biomarkers are also used in clinical practice to stratify patients for treatment and to evaluate response to therapies. The current review summarizes the major clinical utility of current biomarkers in patients with cardiac amyloidosis and provides insights about future areas of investigation.
心脏淀粉样变性是一个不断发展的领域，在诊断和管理方面都有进展。心脏生物标志物用于预测生存率和制定严重程度分期系统。心脏生物标志物在临床实践中还用于对患者进行治疗分层以及评估治疗反应。本综述总结了当前生物标志物在心脏淀粉样变性患者中的主要临床应用，并提供了关于未来研究领域的见解。
